Deciphera sees NDA submission for Vimseltinib in 2Q24

Deciphera expects to submit NDA for Vimseltinib in Q224 and MAA in Q324 in Tenosynovial Giant Cell Tumor TGCT…Results from exploratory ctDNA analysis from INTRIGUE Phase 3 study in 2L GISTpatients with mutations in KIT Exon 11+17/18 published in Nature Medicine; Final overall survival OS results from INTRIGUE study in 2L GIST patients presented at ASCO GI; Cash expected to fund operating and capital expenditures into 2H26…